Physician profile
Alan Ogden Marcus
NPI 1275631657
$118,524.49
in general payments reported to CMS, 2019-2025
85 companies · $5,243 in 2025
The $5,243 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $20K · 2021: $15K · 2022: $11K · 2023: $15K · 2024: $4,573 · 2025: $5,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,200 · Honoraria: $4,400 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,819.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,200.00 |
| Honoraria | $4,400.00 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $68,693.34 | 2019-2025 | Korlym |
| Mannkind Corporation | $15,581.31 | 2019-2025 | Afrezza |
| Vertex Pharmaceuticals Incorporated | $5,541.67 | 2019 | |
| Abbvie INC. | $3,833.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,653.27 | 2019-2025 | Fasenra, Farxiga, Airsupra |
| Novo Nordisk INC | $2,527.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,849.99 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Amgen INC. | $1,677.40 | 2019-2025 | Repatha, Evenity, Tepezza |
| Aimmune Therapeutics, INC. | $1,490.75 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $1,273.80 | 2021-2023 | |
| Dexcom, INC. | $870.41 | 2020-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $800.22 | 2019-2025 | Jardiance |
| Harmony Biosciences LLC | $702.65 | 2021-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $678.56 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $622.01 | 2019-2024 | Xarelto |
Show all 84 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.